The EINSTEIN-PE trial: Rivaroxaban to treat pulmonary embolism [Classics Series]
Image: PD 1. Rivaroxaban, an oral factor Xa inhibitor, was non-inferior to standard anticoagulation therapy (i.e. low-molecular weight heparin and ...
Image: PD 1. Rivaroxaban, an oral factor Xa inhibitor, was non-inferior to standard anticoagulation therapy (i.e. low-molecular weight heparin and ...
Image: PD 1. Rivaroxaban is non-inferior to standard therapy of enoxaparin and vitamin K antagonist in treating acute, symptomatic deep-vein ...
Feb 6th - NEJM - Extended-duration rivaroxaban was superior to standard-duration enoxaparin for thromboprophylaxis, but was associated with increased bleeding ...
1. Rivaroxaban is non-inferior to warfarin in preventing strokes and systemic embolism. 2. Although there is no significant difference between ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.